

Title (en)

USE OF BASTADIN FOR STIMULATING NERVE CELL GROWTH

Title (de)

VERWENDUNG VON BASTADIN ZUR ERREGUNG DES NERVENZELLENWACHSTUMS

Title (fr)

UTILISATION DE LA BASTADINE POUR LA STIMULATION DE LA CROISSANCE DE CELLULES NERVEUSES

Publication

EP 1200078 A1 20020502 (EN)

Application

EP 00947081 A 20000707

Priority

- US 0018539 W 20000707
- US 14318099 P 19990709

Abstract (en)

[origin: WO0103692A1] Neurite outgrowth and nerve regeneration are promoted by disruption of the steroid receptor complex and stimulation of MAP kinase/kinase activity. This disruption can take the form of disruption of the physical assembly or function of the steroid receptor complex, such as the mature complex or a precursor of the mature complex that is required for assembly of the mature complex. Geldanamycin and its analogs, bastadin and members of the bastadin family, and radicicol and its analogs, as well as FKBP-52 antibody, are shown to disrupt the complex and promote nerve growth. Assays for finding neurotrophic compounds, as well as compounds found by these assays, pharmaceutical compositions into which they are incorporated, and methods of treating subjects having neuronal dysfunction caused by injury or disease are disclosed. Any of these compounds can be used in combination with a therapeutically effective amount of heat, such as heat applied locally to an area where nerve growth is desired, or systemically in an organism in which neurite growth is desired. Alternatively, these compounds can be used in association with a template, such as a tubular member that defines an anatomic pathway along which nerve regeneration is desired (particularly around transected or partially transected nerve).

IPC 1-7

A61K 31/21; **A61K 31/365**; **A61K 31/165**; **A61K 38/18**; **A61K 38/00**

IPC 8 full level

A61K 31/165 (2006.01); **G01N 33/50** (2006.01); **A61K 31/00** (2006.01); **A61K 31/21** (2006.01); **A61K 31/335** (2006.01); **A61K 31/365** (2006.01); **A61K 31/395** (2006.01); **A61K 31/436** (2006.01); **A61K 31/444** (2006.01); **A61K 38/00** (2006.01); **A61K 38/18** (2006.01); **A61K 45/00** (2006.01); **A61P 25/00** (2006.01); **A61P 43/00** (2006.01); **C12Q 1/48** (2006.01); **G01N 33/15** (2006.01); **A61F 7/00** (2006.01)

CPC (source: EP US)

A61K 31/00 (2013.01 - EP); **A61K 31/165** (2013.01 - EP); **A61K 31/21** (2013.01 - EP); **A61K 31/365** (2013.01 - EP); **A61K 31/395** (2013.01 - EP US); **A61K 31/436** (2013.01 - EP); **A61K 31/444** (2013.01 - EP); **A61K 38/185** (2013.01 - EP); **A61P 25/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C12Q 1/48** (2013.01 - EP); **A61F 7/00** (2013.01 - EP); **G01N 2500/00** (2013.01 - EP)

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0103692 A1 20010118; AU 6074800 A 20010130; AU 777997 B2 20041111; CA 2377918 A1 20010118; EP 1200078 A1 20020502; EP 1200078 A4 20040630; JP 2003504330 A 20030204

DOCDB simple family (application)

US 0018539 W 20000707; AU 6074800 A 20000707; CA 2377918 A 20000707; EP 00947081 A 20000707; JP 2001508972 A 20000707